Insight

Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24

ESMO/X

Oct 14, 2024, 12:36

Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24

The European Society for Medical Oncology (ESMO) shared a post on X:

“At ESMO24, updated data of KEYNOTE-716 and CheckMate 76K studies confirm the key role of anti-programmed cell death protein 1 (PD-1)-based immunotherapy in the adjuvant setting for patients with melanoma.”

Read further.

More posts featuring ESMO.

cancer CheckMate 76K ESMO ESMO24 KEYNOTE-716 Melanoma OncoDaily Oncology The European Society for Medical Oncology

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

RSS Feed

Youtube

Science

Feb 22, 2025, 13:28

Elvina Almuradova: Immunotherapy for HPV-Associated Cancers

Opinion

Feb 22, 2025, 13:10

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

Science

Feb 22, 2025, 13:10

Why immunotherapy has struggled in EGFR+ lung cancer - EGFR Positive Lung Cancer UK

Blog

Feb 22, 2025, 13:04

Debate session on the management of stage III NSCLC in the IO era - ESTRO

Celebrities

Feb 22, 2025, 11:40

Remembering Saxophonist James Casey: His Battle with Colon Cancer and Advocacy

Career

Feb 22, 2025, 11:36

Joseph H. Antin Received ASTCT Lifetime Achievement Award at 2025 Tandem Meetings

Science

Feb 22, 2025, 11:28

Myeloma Paper of the Day, February 22nd, suggested by Robert Orlowski

Blog

Feb 22, 2025, 11:22

Yan Leyfman: Great experience speaking at the NSHSS Pre-Medicine Workshop

Insight

Feb 22, 2025, 11:15

Henrik Ullum: The urgent need to protect WHO is also an opportunity

Oncolibrary

Feb 22, 2025, 11:02

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

Blog

Feb 22, 2025, 10:57

Tsetsegsaikhan Batmunkh: Factsheets for parents on childhood cancers and essential medicines in the Mongolian

Blog

Feb 22, 2025, 10:47

Akhilesh Bind: Advancing political leadership for equitable cancer care